top of page

NEWS & EVENTS

Onward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints

Emercell NK-001 (OT-C001) project selected as part of France 2030 plan “Biotherapies and bioproduction of innovative therapies"

Onward Therapeutics To Present at the Swiss Biotech Day 2023 on April 25, 2023

Sep 23, 2022

Our affiliate Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Onward Therapeutics Made a Second Strategic Equity Investment in Emercell for Their NK Cell Technology in Cancer Immunotherapy

Onward Therapeutics Signs an Exclusive Collaboration and Worldwide Option and License Agreement with Institut du Cancer de Montpellier

Onward Therapeutics SA opened a wholly owned affiliate, Onward Therapeutics France SAS in Paris, France

Feb 17, 2021

Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy

Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology

bottom of page